GlassScriptPhysician profile
Mohammad Golparian
NPI 1174510002
$2,291.11
in general payments reported to CMS, 2019-2025
38 companies · $177 in 2025
The $177 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $279 · 2020: $151 · 2021: $373 · 2022: $608 · 2023: $392 · 2024: $311 · 2025: $177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $881.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $880.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $307.10 | 2019-2023 | Eliquis |
| Amgen INC. | $226.55 | 2020-2025 | Evenity, Prolia, Otezla |
| Abbott Laboratories | $184.58 | 2020-2023 | Freestyle Libre 2 |
| Astrazeneca Pharmaceuticals LP | $154.95 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $150.62 | 2019-2025 | |
| Glaxosmithkline, LLC. | $148.60 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Paratek Pharmaceuticals, INC. | $106.26 | 2024 | Nuzyra |
| Lilly USA, LLC | $88.06 | 2021-2024 | Mounjaro, Zepbound |
| Stryker Corporation | $58.76 | 2021 | |
| Sanofi-Aventis U.S. LLC | $56.87 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $53.37 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $50.95 | 2022 | |
| Horizon Therapeutics Plc | $50.51 | 2023 | Krystexxa |
| Scilex Pharmaceuticals INC. | $47.88 | 2019-2022 | |
| Lucid Diagnostics INC. | $45.91 | 2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $45.72 | 2024-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $44.93 | 2021 | |
| Astellas Pharma US INC | $43.29 | 2023 | Myrbetriq, Veozah |
| Kowa Pharmaceuticals America, INC. | $38.71 | 2019-2025 | Zoryve |
| Teva Pharmaceuticals USA, INC. | $35.89 | 2020-2024 | Austedo Xr |
| Pfizer INC. | $31.58 | 2020-2023 | |
| Phadia US INC. | $30.44 | 2019 | |
| Radius Health, INC. | $24.98 | 2021 | |
| Allergan, INC. | $24.77 | 2020 | |
| Boston Scientific Corporation | $23.04 | 2020 | |
| Sumitomo Pharma America, INC. | $22.77 | 2023 | Gemtesa |
| Nestle Healthcare Nutrition INC. | $22.35 | 2022 | |
| Neurelis, INC. | $22.00 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.39 | 2021 | |
| Amarin Pharma, INC. | $16.82 | 2019 | |
| Alfasigma USA, INC. | $16.38 | 2020 | |
| Bioventus LLC | $15.88 | 2021 | |
| Sunovion Pharmaceuticals INC. | $15.49 | 2019 | |
| Team_makena_llc | $14.37 | 2020 | |
| Ge Healthcare | $14.28 | 2019 | |
| Tactile Systems Technology INC | $13.57 | 2019 | |
| Merck Sharp & Dohme LLC | $12.18 | 2019 | |
| Esperion Therapeutics, INC. | $11.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Golparian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.